Finding the perfect match: Directed AAV vector development guided by Targeted High Expression

被引：0
|
作者：
Westhaus, A. [1 ,2 ]
Sallard, E. [1 ,3 ]
Cabanes-Creus, M. [1 ]
Rybicki, A. [1 ]
Santilli, G. [2 ]
Thrasher, A. J. [2 ]
Lisowski, L. [1 ,4 ]
机构：
[1] Childrens Med Res Inst, Westmead, NSW, Australia
[2] UCL Inst Child Hlth, London, England
[3] Ecole Normale Super Paris, Paris, France
[4] Mil Inst Hyg & Epidemiol, Warsaw, Poland
来源：
HUMAN GENE THERAPY | 2019年 / 30卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P019
引用
收藏
页码：A24 / A24
页数：1
相关论文
共 50 条
  • [21] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Dongfang Wang
    Hangjun Ruan
    Lily Hu
    Kathleen R Lamborn
    Eileen L Kong
    Alnawaz Rehemtulla
    Dennis F Deen
    Cancer Gene Therapy, 2005, 12 : 276 - 283
  • [22] Chemically-Defined, High-Density Insect Cell-Based Expression System for Scalable AAV Vector Production
    Kurasawa, James
    Park, Andrew
    Sowers, Carrie
    Halpin, Rebecca
    Tovchigrechko, Andrey
    Dobson, Claire
    Schmelzer, Albert
    Gao, Changshou
    Wilson, Susan
    Ikeda, Yasuhiro
    MOLECULAR THERAPY, 2020, 28 (04) : 200 - 200
  • [23] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Wang, DF
    Ruan, HJ
    Hu, L
    Lamborn, KR
    Kong, EL
    Rehemtulla, A
    Deen, DF
    CANCER GENE THERAPY, 2005, 12 (03) : 276 - 283
  • [24] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Wang, DF
    Ruan, HJ
    Hu, L
    Lamborn, KR
    Rehemtulla, A
    Deen, DF
    CANCER GENE THERAPY, 2004, 11 (12) : 857 - 857
  • [25] Development of Optimized AAV2 Vector Biosynthesis and Purification Processes To Support High Capacity Production of Clinical Vectors of High Purity and Potency
    Hauck, Bernd
    Bajaj, Jitin
    Joyce, Sonali
    Qu, Guang
    Zelenaia, Olga A.
    High, Katherine A.
    Wright, J. Fraser
    MOLECULAR THERAPY, 2006, 13 : S196 - S196
  • [26] Development of an Assay to Perform High-Throughput Drug Screen in HEK293 Cells to Improve AAV Vector Production
    Panthi, Santosh
    Baer, Alan
    Bhattarai, Nirjal
    MOLECULAR THERAPY, 2024, 32 (04) : 711 - 711
  • [27] Development of SHP648, Shire's high performing AAV8-based FIX gene therapy vector
    Horling, F.
    Falkner, F. G.
    Chuah, M.
    Lengler, J.
    Mayrhofer, J.
    Klugmann, M.
    de la Rosa, M.
    Coulibaly, S.
    Hoellriegl, W.
    Monahan, P. E.
    VandenDriessche, T.
    Scheiflinger, F.
    Rottensteiner, H.
    HUMAN GENE THERAPY, 2017, 28 (12) : A18 - A18
  • [28] GENE-TRANSFER AND HIGH-LEVEL EXPRESSION OF A HUMAN GAMMA GLOBIN GENE MEDIATED BY A NOVEL ADENOASSOCIATED VIRUS (AAV) VECTOR
    WALSH, CE
    LIU, JM
    YOUNG, NS
    NIENHUIS, AW
    SAMULSKI, RJ
    CLINICAL RESEARCH, 1991, 39 (02): : A325 - A325
  • [29] AN EBV-BASED VECTOR ALLOWING A HIGH-LEVEL OF LTR(HIV)-DIRECTED EXPRESSION IN HUMAN-CELLS
    RAIMOND, J
    PLESSIS, C
    FARGETTE, F
    LEGRAND, A
    HEBERT, E
    PLASMID, 1994, 32 (01) : 70 - 74
  • [30] AAV transfers human blue cone opsin promoter targeted reporter gene expression to rat S-cone photoreceptors with high efficiency
    Glushakova, LG
    Timmers, AM
    Doyle, TD
    Li, Q
    Chiodo, V
    Hauswirth, WW
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U87 - U87
12345